Expand MCRB Menu
MCRB MENU

MCRB Latest Press Releases

-- August 5, 2026 --

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs Globe Newswire 7:00 AM

-- July 8, 2026 --

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment Globe Newswire 7:00 AM

-- June 25, 2026 --

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis Globe Newswire 7:00 AM

-- June 5, 2026 --

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 Globe Newswire 7:00 AM

-- May 12, 2026 --

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference Globe Newswire 7:00 AM

-- May 5, 2026 --

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:00 AM

-- May 4, 2026 --

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease Globe Newswire 7:00 AM

-- April 20, 2026 --

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 Globe Newswire 7:00 AM

-- April 9, 2026 --

Seres Therapeutics to Present at CARB-X Investor Day Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes